India, Sept. 1 -- In an interview to Rhythma Kaul, pharmaceuticals export promotion council of India, or Pharmexcil, vice chairman Bhavin Mehta speaks about the challenges the country's pharma exports are likely to face in the wake of the US tariff threat looming over the sector. He also talks about the impact of UK-India FTA (free trade agreement), India's export potential in regulated markets, and its dependence on APIs (active pharmaceutical ingredients) from other countries. Edited excerpts: While pharmaceuticals have been exempted from the recent tariff measures, any future imposition of a 25% duty would significantly impact India's competitive edge in the US market. The US is one of the largest destinations for Indian pharma exports, ...